Addition of bevacizumab to conventional therapy improved progression-free survival in HER2-positive breast cancer
Thursday, December 8, 2011 - 11:31
in Health & Medicine
SAN ANTONIO -- Data evaluated by an independent review committee revealed that the addition of bevacizumab to trastuzumab and docetaxel significantly improved progression-free survival in...